Cover page & Director's Report - Central Drug Research Institute

More documents

Recommendations

Info

Performance ReportCandidate Drugs under Advance Stages of DevelopmentDiseases /DisordersCandidateDrugsEfficacy Clinical Status Licensees &CollaboratorsLiver Disorder Picroliv Hepatoprotective Phase III clinical trial completed at CSSMU,Lucknow and Seth GS Medical College & KEMHospital Mumbai.DIL, MumbaiDyslipidemia 80-574 +AtorvastatinAnti-dyslipidemicPermission awaited from DCG(I) for extendedphase III clinical trial.CadilaPharmaceuticalsLtd., AhmedabadMalaria 97-78 Antimalarial Phase-I single dose clinical study completed.DCG(I) approval received for single dosepharmacokinetic study in healthy volunteers asper revised protocol.Diabetes CDR 134D123 Antihyperglycemic Phase-I single & multiple dose studies completed;Report submitted to AYUSH; and has beenreferred to Extra Ayurvedic PharmacopiaCommittee for inclusion.IPCA Labs.,MumbaiTVC Sky Shop Ltd.,MumbaiDiabetes &DyslipidemiaCDR 134F194 Antihyperglycemic Modified dossier submitted to DCG(I) – INDCommitteeTVC Sky Shop Ltd.,MumbaiOsteoporosis 99-373 Anti-osteoporotic Plan and protocol of phase I clinical trial has beenapproved by DCG(I).Malaria 99-411 Antimalarial Pre-clinical data is under compilation for INDsubmission.Open for licensingIPCA Labs., MumbaiStrokeHerbalMedicamentNeuroprotective IND application is under preparation. Themis MedicareLtd., MumbaiDiseases /DisordersLeadCompoundPotential New LeadsEfficacy Status Licensees &CollaboratorsOsteoporosis S-007-1500 Fracture healing Single dose toxicity study in rat and mice by oralroute completed. Compound found safe at 50and 100 mg/kg body weight respectively.Osteoporosis 914-K058 Osteogenic Mode of action elucidated; 5 mg/kg daily oraldose stimulated bone formation comparable todaily injection of parathyroid hormone.Under negotiationUnder negotiationBone FractureRepair4669 Bone anabolicagentEfficiency established in experimental models (invitro / in vivo).Open for licensingDiabetes &Dyslipidemia4655-K09 Antidyslipidemic Wide dosage range efficacy established. Open for licensingThrombosisS-002-333 &S-007-867AntithromboticEfficacy and mechanism of action established;Single dose toxicity study in rat by oral routecompleted and both the compounds found safeat 600 mg/kg body weight.Under negotiationContraception S-003-296 Spermicidal Efficacy established; Indian patent granted. Open for licensingCancer S-009-131 Anti-cancer IC 50 < 3 µg/mL for cervical cancer cell line. Nontoxicfor normal cell and breast cancer (SI >10).Tuberculosis S-006-830 Antituberculosis MIC < 3 µg/mL for Mtb H37Rv. Efficacyestablished in vitro & ex vivo.Open for licensingOpen for licensingiiCDRI-CSIR
Performance ReportTotal No. of Publications300250197233 236297244*2001501005002006 2007 2008 2009 2010Impact Factor-wise No. of Publications 2010*Average Impact Factor2.89*2.9IF 3-4: 662.72.592.57IF 4-5: 152.52.37IF >5: 14IF 2-3: 902.32.13IF
Page 1 and 2: ISSN 0972-1789Central Drug Research
Page 3 and 4: 2010-11Central Drug Research Instit
Page 5 and 6: Central Drug Research Institute, CS
Page 13: New Inter-Agency Projects Initiated
Page 18 and 19: Performance ReportIndian Patents*16
Page 20 and 21: Performance ReportBUDGET2010-2011 (
Page 22 and 23: Performance ReportManpowerTotal Sta
Page 24 and 25: Performance ReportSETTING UP OF WOR
Page 26: Performance ReportManagement Counci

Cover page & Director's Report - Central Drug Research Institute

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?